Regulatory filing
China accepts zepuxitini filing in rheumatoid arthritis
China's drug evaluation center has accepted a marketing application for zepuxitini, a selective JAK1 inhibitor partnered by Simcere and Lingke, for active rheumatoid arthritis of moderate or severe grade. The filing rests on phase 3 data from 430 patients showing a significant edge over placebo, with responses holding to week 76. It is the drug's second Chinese filing after atopic dermatitis in April.
Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.